Life Sciences Intellectual Property Review is published by: Newton Media Limited Kingfisher House, 21-23 Elmfield Road, Bromley, BR1 1LT, United Kingdom Telephone: +44 203 301 8200
Director and publisher Nicholas Lipinski
Editor Peter Scott
Telephone: +44 203 301 8211 Email:
pscott@newtonmedia.co.uk
Journalist Ed Conlon
Sub-editor Ros Bromwich
Editorial assistant Rachael Steven
Associate publisher John Haley
Telephone: +44 203 301 8205 Email:
jhaley@worldipreview.com
Advertising manager Matt Saunders
Telephone: +44 1976 423 781 Email:
msaunders@worldipreview.com
Subscription and circulation manager James Lynn
jlynn@newtonmedia.co.uk
Project managers Carlos Northon
cnorthon@worldipreview.com Steve Aslett
saslett@worldipreview.com Tom Curtiss
tcurtiss@worldipreview.com
Administrative support Ksenija Nikolic
knikolic@newtonmedia.co.uk
Production and design Fisherman Creative
©Newton Media Limited 2012
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electrical, mechanical, photocopying,
recording or otherwise without the prior written permission of the publisher.
The views expressed in Life Sciences Intellectual Property Review are not necessarily those shared by the publisher, Newton Media Limited. Wishing to reflect the true nature of the market, we have included articles from a number of sources, and the views expressed are those of the individual contributors. No responsibility or liability is accepted by Newton Media Limited for any loss to any person, legal or physical, as a result of any statement, fact or figure contained in Life Sciences Intellectual Property Review . This publication is not a substitute for advice on a specific transaction.
The publication of advertisements does not represent endorsement by the publisher.
Life Sciences Intellectual Property Review: ISSN 2049-2359 (Print) Cover image:
istockphoto.com
www.worldipreview.com
When people think of innovative life sciences research, they oſten assume that it takes place in the US, and if not there, then in a handful of European countries such as Germany, the UK and France. While it’s a fair and (today at least) still relatively accurate assumption, things are changing. As companies look to develop their businesses in emerging markets, so some of those markets are developing life sciences industries of their own. It’s very possible that the next great biotech innovation may come from China, India or Russia.
If the articles in Life Sciences IP Review 2012 have anything in common beyond their basic subject, it is this: they look outwards and onwards, to other countries and other laws, other cases and other products.
We hear from Russia about the development of its life sciences industry, which has already borne some significant fruit; from the US about a recent court decision whose ramifications are yet to be seen; from Mexico on the various obstacles, confusions and opportunities that abound in that country; and from the UK, on supplementary protection certificates in Europe (a brave new world!).
Our interview with Joe Damond and Lila Feisee from the Biotechnology Industry Organization gives a really interesting insight into how the changing dynamics of the global life sciences industry have transformed the way in which companies and industry associations have to think about everything from business strategies to outreach work. India in particular, provides both a clear opportunity for life sciences businesses and a threat to their success, with a recent decision in a compulsory licensing case proving particularly concerning. Feisee and Damond explain the organisation’s strategy, and why it has ramped up its international efforts considerably over the past year.
More traditional, but no less relevant for the future of the industry, is our feature on the ‘Boston cluster’. We take a look at the most successful life sciences cluster in the world, and try to understand the role IP plays in that success.
Te life sciences and biotech industry is defined by the fact that it operates at the frontiers. While those frontiers have traditionally been scientific, they are increasingly geographical too. We hope you find Life Sciences IP Review 2012 useful, and as ever, we welcome your feedback.
Peter Scott Editor
EDITORIAL PANEL
Stefan Abel, partner, Bardehle Pagenberg
Roberto Arochi, partner, Arochi Marroquín & Lindner SC
Roberto Barchiesi, president, International AntiCounterfeiting Coalition
Colin Davies, director, Intellectual Property Law Unit, University of Glamorgan
Ronald Faggetter, managing partner, Smart & Biggar/ Fetherstonhaugh
Maurice Gonsalves, partner, Mallesons Stephen Jaques
Richard Gough, partner, Baker & McKenzie
Lewis Gould, partner, Duane Morris LLP
Chris McLeod, director of trademarks, Squire Sanders Hammonds
Jacqueline Needle, partner, Beck Greener
Sergio Olivares, partner, Olivares & Cia
John Pegram, senior principal, Fish and Richardson PC
Rebecca L. Roby, senior director of business affairs, Hard Rock International
Pier Luigi Roncaglia, partner, Studio Legale SIB
Mario Soerensen Garcia, founder and managing partner, Soerensen Garcia Advogados Associados
Paul J. Sutton, co-founding partner, Sutton Magidoff LLP
Geoff Wicks, chief executive officer, NetNames
Stephen Yang, partner, Peksung Intellectual Property
Life Sciences Intellectual Property Review 2012 3
EDITOR’S NOTE New horizons
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64